MedTrace Logo

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT03203473 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer

The drugs involved in this study are:

Nivolumab Ipilimumab

Conditions

  • Renal Cancer

Interventions

DRUG

Ipilimumab

YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells

DRUG

Nivolumab

Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs

Sponsors & Collaborators

Principal Investigators

  • Toni K Choueiri, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-26
Primary Completion
2021-11-30
Completion
2026-06-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203473 on ClinicalTrials.gov